Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 16NETWORK 3INDUSTRY 2NIH 1

Study Type

Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, B-Cell 6Lymphoma 4Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Burkitt Lymphoma 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Hematologic Neoplasms 1

Interventions

tisagenlecleucel 8Cyclophosphamide 7fludarabine 5blinatumomab 5aflibercept 4ibrutinib 2epratuzumab 2Vincristine 2Radioimmunodetection 2Methotrexate 2MLN 8237 2Inotuzumab Ozogamicin 2Dexamethasone 2tocilizumab 1tafasitamab 1siltuximab 1sepantronium 1ruxolitinib 1relatlimab 1pembrolizumab 1pegaspargase 1ontuxizumab 1obinutuzumab 1loncastuximab tesirine 1forodesine 1fludarabine phosphate 1fiu protein, E coli 1exatecan 1brexucabtagene autoleucel 1asparaginase erwinia chrysanthemi recombinant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Burkitt Lymphoma × Inotuzumab Ozogamicin × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

NCT05597085 2025-02-04

A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment

Pfizer

Completed
32 enrolled 31 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡